Inventor · disambiguated record
Zhi-Liang Chu
Also filed as: CHU ZHI L · CHU ZHI-LIANG
20 granted patents·11 pending applications·70 citations·filing 2001–2023
94Inventor score
Top patents by PatentIndex Score
31 records- 0187US7803753B2Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 levelARENA PHARM INC·Filed 2006·Granted Sep 28, 2010·6 cites·11 claims
- 0285US8198232B2Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 levelCHU ZHI-LIANG·Filed 2009·Granted Jun 12, 2012·5 cites·66 claims
- 0385US6953691B2Nucleic acid molecule encoding a PANG6 polypeptideBURNHAM INST·Filed 2004·Granted Oct 11, 2005·19 cites·4 claims
- 0483US8354241B2Methods for identifying a GLP-1 secretagogueARENA PHARM INC·Filed 2006·Granted Jan 15, 2013·5 cites·30 claims
- 0583US7833730B2Methods of using GPR119 to identify compounds useful for increasing bone mass in an individualARENA PHARM INC·Filed 2007·Granted Nov 16, 2010·4 cites·69 claims
- 0682US7816364B2GRP119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating theretoARENA PHARM INC·Filed 2007·Granted Oct 19, 2010·4 cites·171 claims
- 0781US8030270B2Methods for identifying GLP-1 secretagoguesARENA PHARM INC·Filed 2009·Granted Oct 4, 2011·2 cites·9 claims
- 0881US8022034B2Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 levelARENA PHARM INC·Filed 2009·Granted Sep 20, 2011·2 cites·34 claims
- 0981US8003597B2Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 levelARENA PHARM INC·Filed 2009·Granted Aug 23, 2011·2 cites·30 claims
- 1080US8101626B2GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating theretoCHU ZHI-LIANG·Filed 2010·Granted Jan 24, 2012·4 cites·38 claims
- 1180US7803754B2Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 levelARENA PHARM INC·Filed 2006·Granted Sep 28, 2010·2 cites·24 claims
- 1279US8580526B2Methods of using GPR119 receptor to identify compounds which stimulate glucose-dependent insulinotropic peptide secretionCHU ZHI-LIANG·Filed 2011·Granted Nov 12, 2013·3 cites·33 claims
- 1379US7838254B2Methods of using GPR119 to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYYARENA PHARM INC·Filed 2009·Granted Nov 23, 2010·2 cites·27 claims
- 1478US8486646B2Methods of using a G protein-coupled receptor to identify peptide YY (PYY) secretagoguesCHU ZHI-LIANG·Filed 2010·Granted Jul 16, 2013·3 cites·166 claims
- 1577US8026212B2Methods of preparing pharmaceutical compositions comprising GPR119 agonists having the effect of glucose-dependent insulinotropic peptide secretatgoguesARENA PHARM INC·Filed 2010·Granted Sep 27, 2011·2 cites·26 claims
- 1677US8026074B2Methods of using GPR119 to identify compounds useful for increasing bone mass in an individualARENA PHARM INC·Filed 2010·Granted Sep 27, 2011·2 cites·17 claims
- 1777US8017574B2Methods of preparing pharmaceutical compositions comprising GPR119 agonists having the effect of glucose-dependent insulinotropic peptide secretagoguesARENA PHARM INC·Filed 2010·Granted Sep 13, 2011·2 cites·36 claims
- 1871US9182414B2Methods for identifying a GLP-1 secretagogueARENA PHARM INC·Filed 2012·Granted Nov 10, 2015·1 cites·52 claims
- 1967US2010137293A1Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 levelARENA PHARM INC·Filed 2009·Application pending·0 cites
- 2065US2007134764A1Endogenous and non-endogenous version of human G protein-coupled receptorsARENA PHARM INC·Filed 2006·Application pending·0 cites
- 2160US2014162358A2Endogenous and Non-Endogenous Versions of Human G Protein-Coupled ReceptorsARENA PHARM INC·Filed 2013·Application pending·0 cites
- 2259US8883714B2Pharmaceutical compositions comprising GPR119 agonists which act as peptide YY (PYY) secretagoguesARENA PHARM INC·Filed 2013·Granted Nov 11, 2014·0 cites·11 claims
- 2359US8039219B2Method of using GPR35 to identify metabolic-stabilizing compoundsARENA PHARM INC·Filed 2006·Granted Oct 18, 2011·0 cites·4 claims
- 2459US2006154866A1Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 levelCHU ZHI-LIANG·Filed 2006·Application pending·0 cites
- 2551US2006234350A1Endogenous and non-endogenous versions of human G protein-coupled receptorsARENA PHARM INC·Filed 2006·Application pending·0 cites
- 2649US2025214976A1Gpr35 modulators and uses thereofCROSSIGNAL THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2749US2003077699A1PAAD domain-containing polypeptides, encoding nucleic acids, and methods of useFiled 2001·Application pending·0 cites
- 2846US2011319451A15-Ht6 Receptor and Modulators Thereof for the Treatment of Insulin-Related DisordersLEONARD JAMES N·Filed 2009·Application pending·0 cites
- 2942US2003139588A9Endogenous and non-endogenous versions of human G protein-coupled receptorsFiled 2001·Application pending·0 cites
- 3040US2012208843A1Method of Using GPR35 to Identify Metabolic-Stabilizing CompoundsLEONARD JAMES N·Filed 2011·Application pending·0 cites
- 3136US2008312277A1Gpr41 and Modulators Thereof for the Treatment of Insulin-Related DisordersLEONARD JAMES N·Filed 2005·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Zhi-Liang Chu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →